COPD Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with stable COPD, based on the GOLD 2023 guidelines
- People aged 40 years or older
- People whose breathing test results show a specific pattern of airflow limitation (a post-bronchodilator FEV1/FVC ratio below 70% or below the lower limit of normal)
- People who are able to perform a standard breathing test called spirometry
Who may not be able to join:
- People who have been diagnosed with another chronic lung condition, such as asthma, asthma-COPD overlap, interstitial lung disease, bronchiectasis, or lung cancer
- People for whom breathing tests (spirometry) are not considered safe, including those who have recently had heart complications, major surgery, or severe advanced breathing problems, or those with cognitive or neurological conditions that would make the test difficult
- People who have a known allergy or sensitivity to acetylcysteine or any ingredient in that medication
- People who have a known allergy or sensitivity to dry powder ivy extract
- Women who are pregnant or breastfeeding (pregnancy is confirmed by a positive hCG laboratory test)
- People who have been regularly taking mucolytic medications (medicines that help thin mucus) for at least one month before joining
- People who are unable to read or write
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mohamed Faisal Abdul Hamid, MBBS (IIUM), National University of Malaysia
Phone: 0391455555
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess cough symptoms and its impact on daily activities using Cough and Sputum Assessment Questionnaire (CASA-Q); scores for each domain range from 0 to 100, with higher scores indicating fewer/less severe symptoms and less impact.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.